APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)

21 4 2022 07:00:02 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

28 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

24 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

23 3 2022 16:02:57 提供 Nasdaq GlobeNewswire

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

16 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

02 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

28 2 2022 16:05:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

22 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1 2022 16:05:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 1 2022 07:00:00 提供 Nasdaq GlobeNewswire

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

15 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

13 12 2021 11:45:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

29 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

18 11 2021 16:01:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

16 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

15 11 2021 16:01:00 提供 Nasdaq GlobeNewswire

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

12 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting

10 11 2021 07:00:04 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results

08 11 2021 16:01:00 提供 Nasdaq GlobeNewswire